JP2025096283A5 - - Google Patents

Download PDF

Info

Publication number
JP2025096283A5
JP2025096283A5 JP2025039288A JP2025039288A JP2025096283A5 JP 2025096283 A5 JP2025096283 A5 JP 2025096283A5 JP 2025039288 A JP2025039288 A JP 2025039288A JP 2025039288 A JP2025039288 A JP 2025039288A JP 2025096283 A5 JP2025096283 A5 JP 2025096283A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
drug substance
dose
aat rnai
rnai drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025039288A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025096283A (ja
Filing date
Publication date
Priority claimed from JP2021572103A external-priority patent/JP7697889B2/ja
Application filed filed Critical
Publication of JP2025096283A publication Critical patent/JP2025096283A/ja
Publication of JP2025096283A5 publication Critical patent/JP2025096283A5/ja
Pending legal-status Critical Current

Links

JP2025039288A 2019-06-06 2025-03-12 アルファ-1アンチトリプシン欠乏症(aatd)の治療法 Pending JP2025096283A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962858059P 2019-06-06 2019-06-06
US62/858,059 2019-06-06
JP2021572103A JP7697889B2 (ja) 2019-06-06 2020-06-05 アルファ-1アンチトリプシン欠乏症(aatd)の治療法
PCT/US2020/036359 WO2020247774A1 (en) 2019-06-06 2020-06-05 Methods for the treatment of alpha-1 antitrypsin deficiency (aatd)

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021572103A Division JP7697889B2 (ja) 2019-06-06 2020-06-05 アルファ-1アンチトリプシン欠乏症(aatd)の治療法

Publications (2)

Publication Number Publication Date
JP2025096283A JP2025096283A (ja) 2025-06-26
JP2025096283A5 true JP2025096283A5 (https=) 2025-10-24

Family

ID=73652297

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021572103A Active JP7697889B2 (ja) 2019-06-06 2020-06-05 アルファ-1アンチトリプシン欠乏症(aatd)の治療法
JP2025039288A Pending JP2025096283A (ja) 2019-06-06 2025-03-12 アルファ-1アンチトリプシン欠乏症(aatd)の治療法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021572103A Active JP7697889B2 (ja) 2019-06-06 2020-06-05 アルファ-1アンチトリプシン欠乏症(aatd)の治療法

Country Status (12)

Country Link
US (1) US12582668B2 (https=)
EP (1) EP3980540A4 (https=)
JP (2) JP7697889B2 (https=)
KR (1) KR20220019255A (https=)
CN (1) CN114222820A (https=)
AU (1) AU2020286462A1 (https=)
BR (1) BR112021024534A2 (https=)
CA (1) CA3141762A1 (https=)
CO (1) CO2022000016A2 (https=)
MX (1) MX2021015003A (https=)
TW (1) TW202113081A (https=)
WO (1) WO2020247774A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201620526A (zh) 2014-06-17 2016-06-16 愛羅海德研究公司 用於抑制α-1抗胰蛋白酶基因表現之組合物及方法
BR112019014282A2 (pt) 2017-01-10 2020-03-03 Arrowhead Pharmaceuticals, Inc. Agentes de rnai de antitripsina (aat) alfa-1, composições incluindo agentes de rnai de aat, e métodos de uso
MX2021015003A (es) 2019-06-06 2022-01-24 Arrowhead Pharmaceuticals Inc Metodos para el tratamiento de la deficiencia de alfa-1 antitripsina (aatd).
AU2021345026A1 (en) * 2020-09-15 2023-05-11 Arrowhead Pharmaceuticals, Inc. Methods for the reduction of z-aat protein levels
JP2024532019A (ja) * 2021-08-25 2024-09-05 ノボ ノルディスク エー/エス アルファ-1アンチトリプシン発現を阻害するための組成物及び方法
WO2024044542A2 (en) * 2022-08-22 2024-02-29 Arrowhead Pharmaceuticals, Inc. Methods for the treatment of angptl3-related diseases and disorders
WO2025219443A1 (en) * 2024-04-19 2025-10-23 Uniqure Biopharma B.V. Nucleic acid for a1at regulation

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
AU598946B2 (en) 1987-06-24 1990-07-05 Howard Florey Institute Of Experimental Physiology And Medicine Nucleoside derivatives
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
ATE269870T1 (de) 1989-10-24 2004-07-15 Isis Pharmaceuticals Inc 2'-modifizierte oligonukleotide
US5212295A (en) 1990-01-11 1993-05-18 Isis Pharmaceuticals Monomers for preparation of oligonucleotides having chiral phosphorus linkages
WO1993007883A1 (en) 1991-10-24 1993-04-29 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
EP0577558A2 (de) 1992-07-01 1994-01-05 Ciba-Geigy Ag Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
NL9201440A (nl) 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US6077705A (en) 1996-05-17 2000-06-20 Thomas Jefferson University Ribozyme-mediated gene replacement
US6172209B1 (en) 1997-02-14 2001-01-09 Isis Pharmaceuticals Inc. Aminooxy-modified oligonucleotides and methods for making same
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
AU9063398A (en) 1997-09-12 1999-04-05 Exiqon A/S Oligonucleotide analogues
FR2774379B1 (fr) 1998-01-30 2002-03-29 Groupe Limagrain Holding Procede de production, par des cellules vegetales, d'alpha 1-antitrypsine et de ses variantes, et produits contenant l'alpha-antitrypsine ainsi obtenue
US6271358B1 (en) 1998-07-27 2001-08-07 Isis Pharmaceuticals, Inc. RNA targeted 2′-modified oligonucleotides that are conformationally preorganized
CZ296576B6 (cs) 1999-02-12 2006-04-12 Sankyo Company Limited Nukleosidový analog a oligonukleotidový analog a farmaceutický prostredek, sonda a primer s jeho obsahem
DE60040274D1 (de) 1999-03-10 2008-10-30 Phogen Ltd Verabreichung von nukleinsäuren und proteinen an zellen
US8137695B2 (en) 2006-08-18 2012-03-20 Arrowhead Madison Inc. Polyconjugates for in vivo delivery of polynucleotides
PT1309726E (pt) 2000-03-30 2010-03-08 Whitehead Biomedical Inst Mediadores de interferência por rna específicos de sequência de rna
US20040259247A1 (en) 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
US20050137153A1 (en) * 2002-02-20 2005-06-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of alpha-1 antitrypsin (AAT) gene expression using short interfering nucleic acid (siNA)
EP2305812A3 (en) 2002-11-14 2012-06-06 Dharmacon, Inc. Fuctional and hyperfunctional sirna
CA2519860C (en) 2003-03-21 2018-01-16 Santaris Pharma A/S Short interfering rna (sirna) analogues
WO2005070948A1 (en) 2004-01-23 2005-08-04 Intronn, Inc. Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated rna trans splicing
AU2005222965B8 (en) 2004-03-15 2010-07-01 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
AU2005327506B2 (en) 2004-10-20 2010-07-08 Antisense Therapeutics Ltd Antisense modulation of integrin alpha4 expression
WO2008016391A2 (en) 2006-01-31 2008-02-07 The Board Of Trustees Of The Leland Stanford Junior University Self-complementary parvoviral vectors, and methods for making and using the same
US20100048680A1 (en) 2007-01-11 2010-02-25 University Of Florida Research Foundation Inc. Alpha-1-Antitrypsin Variants and Uses Thereof
BRPI0811170B8 (pt) 2007-05-22 2021-05-25 Arcturus Therapeutics Inc oligonucleotídeos de rna e complexos de rna substituídos por hidroximetila
WO2009082607A2 (en) 2007-12-04 2009-07-02 Alnylam Pharmaceuticals, Inc. Targeting lipids
US20110028531A1 (en) 2008-03-20 2011-02-03 Elena Feinstein Novel sirna compounds for inhibiting rtp801
US20100249214A1 (en) 2009-02-11 2010-09-30 Dicerna Pharmaceuticals Multiplex dicer substrate rna interference molecules having joining sequences
AU2009336191B2 (en) 2008-12-18 2017-08-24 Novo Nordisk A/S Extended dicer substrate agents and methods for the specific inhibition of gene expression
DK2539451T3 (da) 2010-02-24 2016-04-04 Arrowhead Res Corp Sammensætninger til målrettet tilførsel af siRNA
AU2011299233B2 (en) 2010-09-07 2016-09-15 Integrated Dna Technologies, Inc. Modifications for antisense compounds
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
ES2605990T3 (es) 2010-12-29 2017-03-17 F. Hoffmann-La Roche Ag Conjugados de molécula pequeña para la administración intracelular de ácidos nucleicos
EP3366312A1 (en) 2011-06-23 2018-08-29 Alnylam Pharmaceuticals, Inc. Serpina 1 sirnas: compositions of matter and methods of treatment
WO2013032829A1 (en) 2011-08-26 2013-03-07 Arrowhead Research Corporation Poly(vinyl ester) polymers for in vivo nucleic acid delivery
US9340784B2 (en) 2012-03-19 2016-05-17 Ionis Pharmaceuticals, Inc. Methods and compositions for modulating alpha-1-antitrypsin expression
JP2015515530A (ja) 2012-04-18 2015-05-28 アローヘッド リサーチ コーポレイション インビボ核酸送達のためのポリ(アクリラート)ポリマー
TW201936624A (zh) 2013-05-22 2019-09-16 美商阿尼拉製藥公司 絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
WO2014197524A2 (en) 2013-06-06 2014-12-11 Serpin Pharma, Llc Peptide therapy for treatment of alpha-1 antitrypsin deficiency and associated pathologies
DK3444350T3 (da) 2013-07-03 2022-02-07 Dicerna Pharmaceuticals Inc Fremgangsmåder og sammensætninger til specifik hæmning af alpha-1 antitrypsin ved dobbeltstrenget rna
JP2017522046A (ja) 2014-06-06 2017-08-10 ソルスティス バイオロジクス,リミティッド 生物可逆的および生物不可逆的基を有するポリヌクレオチド構築物
TW201620526A (zh) 2014-06-17 2016-06-16 愛羅海德研究公司 用於抑制α-1抗胰蛋白酶基因表現之組合物及方法
KR20180038465A (ko) 2015-08-07 2018-04-16 애로우헤드 파마슈티컬스 인코포레이티드 B형 간염 바이러스 감염에 대한 rnai 치료법
WO2017139616A1 (en) 2016-02-10 2017-08-17 Arrowhead Pharmaceuticals, Inc. Methods of treatment for alpha-1 antitrypsin deficiency
KR102515329B1 (ko) 2016-03-07 2023-03-29 애로우헤드 파마슈티컬스 인코포레이티드 치료용 화합물을 위한 표적화 리간드
EP3469083A1 (en) * 2016-06-10 2019-04-17 Alnylam Pharmaceuticals, Inc. COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
MX2018009853A (es) 2016-09-02 2018-11-09 Arrowhead Pharmaceuticals Inc Ligandos de direccion.
TW202313978A (zh) 2016-11-23 2023-04-01 美商阿尼拉製藥公司 絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
BR112019014282A2 (pt) * 2017-01-10 2020-03-03 Arrowhead Pharmaceuticals, Inc. Agentes de rnai de antitripsina (aat) alfa-1, composições incluindo agentes de rnai de aat, e métodos de uso
SE540888C2 (en) 2017-06-19 2018-12-11 Hepgene Medical Ab Novel nucleic acid molecules and their use in therapy
MX2021015003A (es) 2019-06-06 2022-01-24 Arrowhead Pharmaceuticals Inc Metodos para el tratamiento de la deficiencia de alfa-1 antitripsina (aatd).
AU2021345026A1 (en) 2020-09-15 2023-05-11 Arrowhead Pharmaceuticals, Inc. Methods for the reduction of z-aat protein levels

Similar Documents

Publication Publication Date Title
JP2025096283A5 (https=)
JP2025128190A5 (https=)
JP2022031772A5 (https=)
JP2024153797A5 (https=)
JP2001513514A (ja) 少なくとも1種の二重鎖RNA(dsRNA)を、少なくとも1種の抗ウイルス剤と組合せて含有する製品
JPH11512083A (ja) C型肝炎の治療における1,3−オキサチオランヌクレオシドアナログ
JPWO2020061177A5 (https=)
JPH10500430A (ja) 「呼吸器系疾患の治療方法および治療用薬剤組成物」
BRPI0610873A2 (pt) tratamento de doenças hepáticas em que o ferro desempenhe um papel na patogênese
JPWO2020146362A5 (https=)
JP2002530353A5 (https=)
RU2002105485A (ru) Применение микофенолята мофетила в сочетании с ПЭГ-интерфероном-α (ПЭГ-IFN-α)
JP2007501806A5 (https=)
JPWO2020247774A5 (https=)
JP7369523B2 (ja) 中等度~重度のインフルエンザの処置
JP2023020885A5 (https=)
EP3999069B1 (en) Synergistic effect of eyp001 and pegylated ifn-alpha for the treatment of hbv infection
JP2025500412A (ja) 血友病患者において患者報告アウトカムを改善するのに使用するためのフィツシラン
JPWO2021119522A5 (https=)
RU2021139235A (ru) Способы лечения дефицита альфа-1-антитрипсина (aatd)
JPWO2007013677A1 (ja) インターフェロン作用物質の活性増強剤
JP2003171266A (ja) キシリトールを含有する解熱性調剤
JP2020045332A (ja) 慢性便秘症を治療するための医薬組成物
JPWO2022060721A5 (https=)
CN110841069A (zh) 一种含有沙利度胺与抗真菌药物的药物组合物及应用